Skip to content
Research

Clinical Studies

Peer-reviewed research validating Sonopeace's bone conduction frequency technology for sleep improvement.

35
participants
7
week study
6
validated measures
IRB-approved, double-blind, placebo-controlled
Key Findings

Results from the 2025 clinical trial

+11% Deep Sleep Duration p=0.017
106% More Sleep Improvement vs Placebo PROMIS, p=0.020
37% Achieved Insomnia Remission ISI
0 Adverse Effects Reported All participants
Clinical Data

Results in detail

Data from our double-blind, placebo-controlled cross-over study with 35 participants.

Sleep Impairment

PROMIS T-Score by treatment sequence

Sonopeace first produces 106% more improvement vs Placebo (p=0.020, d=0.72). Benefits persist after switching to Placebo.

Insomnia Severity

Participant severity distribution over time

37% achieved full remission from clinical insomnia (ISI <8). 10 participants moved from clinical insomnia to no insomnia.

Objective Sleep

Deep sleep duration

+11% deep sleep with Sonopeace (p=0.017, d=0.23).

Subjective Quality

Nightly self-reported sleep measures

4.9 → 1.8 awakenings per night (-63%)

Participants reported feeling 3x more rested. Nightly awakenings dropped from 4.9 to 1.8 per night (-63%).

Clinical Outcomes

Responder and remission rates

Over one-third of participants achieved clinically meaningful improvement by study end.

Effect Sizes

Overall improvement: Baseline to end of study

Pre-post effect sizes (Baseline → Period 2, all participants). Both treatment conditions improved; the Sonopeace-specific treatment effect is captured in Chart 1.

Study Details

Primary Study

Effects of Low-Frequency Bone Conduction Stimulation on Sleep Quality: A Double-Blind, Placebo-Controlled Cross-Over Study

SleepScore Labs IRB-Approved 2025

A 7-week study with 35 participants examining the effects of Sonopeace's frequency technology on objective and subjective sleep measures. The study used a cross-over design where each participant served as their own control.

Study Design

  • Double-blind, placebo-controlled cross-over design
  • 35 participants (ages 25-65, chronic sleep difficulties)
  • 7-week duration with 2-week washout period
  • Sleep measured using SleepScore Max (contactless biomotion sensor)
  • Validated clinical questionnaires: PROMIS, PSQI, ISI, ESS
  • No evidence of residual effects or habituation

Key Findings

  • Statistically significant improvement in deep sleep duration (p=0.017) and overall sleep score (p=0.028)
  • PROMIS showed 106% greater improvement with Sonopeace versus Placebo (p=0.020, medium-to-large effect)
  • 37% of participants with clinical insomnia achieved full remission
  • Benefits appear durable: improvements persisted after discontinuation (carryover effect)
  • No adverse effects reported by any participant
Bone Conduction Sleep Quality Placebo-Controlled Cross-Over
Download Full Study
Statistical Analysis

Independent Statistical Review of Sonopeace Sleep Study Data

Mereon Legacy CIC, UK Peter A. McNair, MD, Dr.Med.Sci. 2025

Independent statistical analysis of the primary study data conducted by Dr. Peter A. McNair. Confirmed the statistical significance of results across multiple sleep quality measures and validated the study methodology.

Analysis Scope

  • Full re-analysis of raw study data from SleepScore Labs trial
  • Verification of statistical significance across all endpoints
  • Assessment of effect sizes and clinical relevance
  • Evaluation of cross-over design validity and washout adequacy
Statistical Review Independent Peer Review
2012 - 2020

The road to clinical proof

Over a decade of independent studies built the foundation for our 2025 clinical trial.

2012

Sound Pattern Investigation (Cymatics)

Scientists resonated water with a specific frequency and discovered it produced patterns matching the sonic signatures of the human heart and brain, the first evidence that structured sound could interact with biological rhythms.

Read the study
2015

Field Experiment, Davis, California

In an open-format field test, participants reported reduced stress, increased focus, and a profound sense of relaxation after listening to Sonopeace frequencies, igniting the formal scientific investigation.

Watch the video
2016 - 2018

Meditation Study, 22 Participants

A multi-year study demonstrated heightened clarity, deeper relaxation, and improved focus among participants. The results led directly to a biofeedback collaboration with Dr. Andres Muñoz in Spain.

Read the study
2018

Neuro/Cardio Biofeedback Study

Dr. Andres Muñoz in Marbella, Spain used EEG, HRV, electrodermal activity, and diaphragmatic breathing measurements. Found increased Alpha/Theta ratio, suggesting improved emotional regulation and stress reduction.

Read the study
2020

Neuropsychological Study with Biodevices

Francisco Marques Teixeira expected to find Theta wave activity but discovered that most participants entered a Delta state, the brainwave pattern associated with deep sleep. Biofeedback devices independently confirmed the finding.

Read the presentation
Research Standards

How we conduct research

Study oversight

  • IRB: Sterling Institutional Review Board, Protocol #13207
  • Principal Investigator: Peter A. McNair, MD, Dr.Med.Sci., The Mereon Legacy CIC

Measurement instruments

  • Objective: SleepScore Max non-contact radar (sleep stages, duration, efficiency)
  • Subjective: PROMIS Sleep-Related Impairment, PSQI, ISI, ESS
  • Nightly: Visual Analog Scale for sleep quality, restedness, relaxation, awakenings

Data transparency

  • All studies follow established clinical research protocols
  • Sonopeace is committed to transparent reporting of research findings, including placebo effects
  • For questions about our research, contact research@sonopeace.com

Be the first to experience Sonopeace

Join the waitlist for early access and launch pricing.

Get Early Access Read the whitepaper